Guardant Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Guardant Health (GH).

Price Target Range — 8 Quarters

Analyst Consensus — 25 Analysts

25Buy

Consensus RatingBuy# Analysts25Avg. Consensus PT$167Upside to Avg. PT-10.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$190→$200
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Buy	$175→$225
Sep 8, 2026	Rothschild & Co	Jamie Clark	Initiate	Buy	$203
Sep 2, 2026	BTIG	Mark Massaro	Maintained	Buy	$195
Aug 4, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$135→$193
Aug 4, 2026	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$170→$195
Aug 4, 2026	Morgan Stanley	Shannon O'Callaghan	PT Raise	Overweight	$175→$185
Aug 3, 2026	Stifel	Daniel Arias	PT Raise	Buy	$130→$180
Jul 31, 2026	RBC Capital	Dan Leonard	PT Raise	Outperform	$185→$200
Jul 31, 2026	Mizuho	Anthony Petrone	PT Raise	Outperform	$175→$200
Jul 31, 2026	JP Morgan	Casey Woodring	PT Raise	Overweight	$185→$195
Jul 31, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$200→$210
Jul 31, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$150→$200
Jul 31, 2026	BTIG	Mark Massaro	PT Raise	Buy	$190→$195
Jul 16, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$160→$190
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$135→$205
Jul 9, 2026	Morgan Stanley	Shannon O'Callaghan	PT Raise	Overweight	$130→$175
Jul 8, 2026	Citigroup	Patrick Donnelly	PT Raise	Buy	$150→$215
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$160→$200
Jul 6, 2026	B of A Securities	Michael Ryskin	PT Raise	Buy	$135→$190

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $200.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Guardant Health, Raises Price Target to $225

UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.

Benzinga Newsdesk

PRO
Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

BTIG analyst Mark Massaro reiterates Guardant Health (NASDAQ:GH) with a Buy and maintains $195 price target.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193

Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $135 to $193.

Benzinga Newsdesk

PRO
Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195

Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $170 to $195.

Benzinga Newsdesk

Guardant Health Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Guardant Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

PRO
UBS Maintains Buy on Guardant Health, Raises Price Target to $225

PRO
Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

PRO
BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

PRO
Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193

PRO
Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195

People Also Watch

People Also Watch

Guardant Health Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Guardant Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

PROUBS Maintains Buy on Guardant Health, Raises Price Target to $225

PRORothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

PROBTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

PROPiper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193

PROStephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

PRO
UBS Maintains Buy on Guardant Health, Raises Price Target to $225

PRO
Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

PRO
BTIG Reiterates Buy on Guardant Health, Maintains $195 Price Target

PRO
Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193

PRO
Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195